CRISPR Therapeutics AG (CRSP) Operating Expenses (2015 - 2026)

CRISPR Therapeutics AG has disclosed Operating Expenses across 12 years of filings, most recently posting $131.7 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $131.7 million, down 11.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $650.5 million (up 27.03% YoY), and the FY2025 annual result was $668.1 million, up 32.59% from the prior year.
• Operating Expenses came in at $131.7 million for Q1 2026 at CRISPR Therapeutics AG, down from $155.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $230.2 million in Q2 2025 to a low of $100.3 million in Q4 2024.
• The 5-year median for Operating Expenses is $149.3 million (2025), against an average of $151.3 million.
• Across the five-year window, Operating Expenses decreased 27.44% in 2023 and surged 55.2% in 2025, its largest moves.
• CRISPR Therapeutics AG's Operating Expenses stood at $131.5 million in 2022, then increased by 0.06% to $131.6 million in 2023, then retreated by 23.81% to $100.3 million in 2024, then soared by 55.2% to $155.6 million in 2025, then fell by 15.37% to $131.7 million in 2026.
• The last three Operating Expenses figures came in at $131.7 million (Q1 2026), $155.6 million (Q4 2025), and $132.9 million (Q3 2025), per Business Quant data.